Skip to content

At ACADIA, we are committed to improving the lives of patients with neurological and related central nervous system disorders.

About Us

ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. More »



News

September 02, 2014
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis

August 28, 2014
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin

More News »

Product Candidates

We have a pipeline of product candidates led by NUPLAZID™ (pimavanserin), which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.   More »


 

Company Information

Investor's Kit Learn More: NUPLAZID™ (pimavanserin) Phase III Program for Parkinson's Disease Psychosis »
Investor Webcasts Investor Webcasts »
PDF Corporate Presentation »